Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine

Por Steuten, Lotte M.G.
Publicado no OMICS (2016)

A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers

Por Oosterhoff, Marije, van der Maas, Marloes E., Steuten, Lotte M. G.
Publicado no Appl Health Econ Health Policy (2015)

Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study

Por de Ligt, Kelly M., Witteveen, Annemieke, Siesling, Sabine, Steuten, Lotte M. G.
Publicado no BMC Cancer (2018)

Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands

Por Miquel-Cases, Anna, Steuten, Lotte M. G., Rigter, Lisanne S., van Harten, Wim H.
Publicado no BMC Cancer (2016)

Quality of integrated chronic care measured by patient survey: identification, selection and application of most appropriate instruments

Por Vrijhoef, Hubertus J. M., Berbee, Rieneke, Wagner, Edward H., Steuten, Lotte M. G.
Publicado no Health Expect (2009)

Cost-Effectiveness Analysis of a Procalcitonin-Guided Decision Algorithm for Antibiotic Stewardship Using Real-World U.S. Hospital Data

Por Voermans, Anne M., Mewes, Janne C., Broyles, Michael R., Steuten, Lotte M. G.
Publicado no OMICS (2019)

Effectiveness of Multidimensional Cancer Survivor Rehabilitation and Cost-Effectiveness of Cancer Rehabilitation in General: A Systematic Review

Por Mewes, Janne C., Steuten, Lotte M.G., IJzerman, Maarten J., van Harten, Wim H.
Publicado em 2012

COPD as a multicomponent disease: Inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care

Por Steuten, Lotte M.G., Creutzberg, Eva C., Vrijhoef, Hubertus J.M., Wouters, Emiel F.
Publicado no Prim Care Respir J (2006)

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients

Por Miquel-Cases, Anna, Retèl, Valesca P., Lederer, Bianca, von Minckwitz, Gunter, Steuten, Lotte M. G., van Harten, Wim H.
Publicado no PLoS One (2016)

Comparative cost-effectiveness of focal and total salvage (125)I brachytherapy for recurrent prostate cancer after primary radiotherapy

Por Peters, Max, Piena, Marjanne A., Steuten, Lotte M.G., van der Voort van Zyp, Jochem R.N., Moerland, Marinus A., van Vulpen, Marco
Publicado no J Contemp Brachytherapy (2016)

A Call for Pharmacogenovigilance and Rapid Falsification in the Age of Big Data: Why not First Road Test Your Biomarker?

Por Şardaş, Semra, Endrenyi, Laszlo, Gürsoy, Ulvi K., Hutz, Mara, Lin, Biaoyang, Patrinos, George P., Steuten, Lotte M.G., Wang, Wei, Warnich, Louise, Özdemir, Vural
Publicado no OMICS (2014)

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation

Por Retèl, Valesca P., Steuten, Lotte M. G., Geukes Foppen, Marnix H., Mewes, Janne C., Lindenberg, Melanie A., Haanen, John B. A. G., van Harten, Wim H.
Publicado no BMC Cancer (2018)

Return-to-work intervention for cancer survivors: budget impact and allocation of costs and returns in the Netherlands and six major EU-countries

Por Mewes, Janne C., Steuten, Lotte M. G., Groeneveld, Iris F., de Boer, Angela G. E. M., Frings-Dresen, Monique H. W., IJzerman, Maarten J., van Harten, Wim H.
Publicado no BMC Cancer (2015)

The Effectiveness of Chronic Care Management for Heart Failure: Meta-Regression Analyses to Explain the Heterogeneity in Outcomes

Por Drewes, Hanneke W, Steuten, Lotte M G, Lemmens, Lidwien C, Baan, Caroline A, Boshuizen, Hendriek C, Elissen, Arianne M J, Lemmens, Karin M M, Meeuwissen, Jolanda A C, Vrijhoef, Hubertus J M
Publicado em 2012